Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Ginsberg

Showing results (301-310 of 312) with videos related to

Pageof 32
Sort By:
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
Diabetes|January 25, 2020
<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-LipidMario Luca Morieri, Hetal S Shah, Jennifer Sjaarda, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
European Heart Journal|April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelBrian A Ference, Henry N Ginsberg, Ian Graham, et al.
European Heart Journal|August 20, 2013
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis SocietyBørge G Nordestgaard, M John Chapman, Steve E Humphries, et al.
European Heart Journal|May 3, 2018
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractFrançois Mach, Kausik K Ray, Olov Wiklund, et al.
European Heart Journal|July 24, 2014
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis SocietyMarina Cuchel, Eric Bruckert, Henry N Ginsberg, et al.
European Heart Journal|May 27, 2015
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatmentAlbert Wiegman, Samuel S Gidding, Gerald F Watts, et al.
The New England Journal of Medicine|November 7, 2022
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular RiskAruna Das Pradhan, Robert J Glynn, Jean-Charles Fruchart, et al.
Cardiovascular Diabetology|January 28, 2014
Residual macrovascular risk in 2013: what have we learned?Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, et al.
Pageof 32

Showing results (301-310 of 312) with videos related to

Sort By:
Pageof 32
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
Diabetes|January 25, 2020
<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-LipidMario Luca Morieri, Hetal S Shah, Jennifer Sjaarda, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
European Heart Journal|April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelBrian A Ference, Henry N Ginsberg, Ian Graham, et al.
European Heart Journal|August 20, 2013
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis SocietyBørge G Nordestgaard, M John Chapman, Steve E Humphries, et al.
European Heart Journal|May 3, 2018
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractFrançois Mach, Kausik K Ray, Olov Wiklund, et al.
European Heart Journal|July 24, 2014
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis SocietyMarina Cuchel, Eric Bruckert, Henry N Ginsberg, et al.
European Heart Journal|May 27, 2015
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatmentAlbert Wiegman, Samuel S Gidding, Gerald F Watts, et al.
The New England Journal of Medicine|November 7, 2022
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular RiskAruna Das Pradhan, Robert J Glynn, Jean-Charles Fruchart, et al.
Cardiovascular Diabetology|January 28, 2014
Residual macrovascular risk in 2013: what have we learned?Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, et al.
Pageof 32